-
-
-
-
-
-
-
FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.
-
-
-
-
-
-
-
Median Technologies adds Lion Point Capital founder to board
-
-
-
-
-
-
-
Following the Signature of a Financial Agreement for up to €37.5 Million With the EIB, Median Technologies Launches an Approximately €22.0 Million Capital Increase to Support Commercialization of
-
-
-
-
-
-
-
eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study
-
-
-
-
-
-
-
Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results
-
-
-
-
-
-
-
Median Technologies Reports Its Business Activity for the First Half of 2023 and Announces the First Step of Its Refinancing Plan
-
-
-
-
-
-
-
Median Technologies Reports on Its 2021 Half-Year Results and Its Q3 2021 Business Activity Indicators
-
1,203,405 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

